Kim Doh Hyung, Kim Hee Jin, Park Seung-Kyu, Kong Suck-Jun, Kim Young Sam, Kim Tae-Hyung, Kim Eun Kyung, Lee Ki Man, Lee Sung Soon, Park Jae Seuk, Koh Won-Jung, Lee Chang-Hoon, Kim Ji Yeon, Shim Tae Sun
Department of Internal Medicine, Dankook University College of Medicine, Dankook University Hospital, Cheonan, South Korea.
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82. doi: 10.1164/rccm.200801-132OC. Epub 2008 Aug 14.
The increasing worldwide incidence of extensively drug-resistant tuberculosis (XDR-TB) has emerged as a threat to public health and tuberculosis (TB) control. Treatment outcomes have varied among studies, and data on long-term survival are still scarce.
To retrospectively assess the burden, clinical characteristics, treatment outcomes, and long-term survival rate of patients with XDR-TB in a cohort of patients with HIV-negative multidrug-resistant tuberculosis (MDR-TB) in South Korea.
Medical records were reviewed of patients newly diagnosed with or retreated for MDR-TB from 2000 to 2002. The cohort was monitored for 3 to 7 years after the initiation of treatment. Initial treatment outcomes and cumulative survival rates were analyzed, and predictors of treatment success and survival were defined.
Of 1,407 patients with MDR-TB 75 (5.3%) had XDR-TB at treatment initiation. The default rate was high (453/1,407; 32%), and patients with XDR-TB had lower treatment success (29.3 vs. 46.2%; P = 0.004) and higher all-cause (49.3 vs. 19.4%; P < 0.001) and TB-related disease mortality (41.3 vs. 11.8%; P < 0.001) than other patients with MDR-TB. The presence of XDR-TB significantly affected treatment success (odds ratio, 0.23; 95% confidence interval [CI], 0.08-0.64; P = 0.005), all-cause mortality (hazards ratio, 3.25; 95% CI, 1.91-5.53; P < 0.001), and TB-related mortality (hazards ratio, 4.45; 95% CI, 2.48-8.00; P < 0.001) on multivariate analyses.
XDR-TB occurred in a substantial proportion of patients with MDR-TB in South Korea, and was the strongest predictor of treatment outcomes and long-term survival in patients with MDR-TB. Adequate TB control policies should be implemented to prevent the further development and spread of drug resistance.
全球范围内广泛耐药结核病(XDR-TB)发病率的上升已成为对公共卫生和结核病(TB)控制的一大威胁。不同研究的治疗结果各异,关于长期生存的数据仍然匮乏。
回顾性评估韩国一组HIV阴性耐多药结核病(MDR-TB)患者中XDR-TB患者的负担、临床特征、治疗结果及长期生存率。
对2000年至2002年新诊断或接受MDR-TB治疗的患者的病历进行回顾。在治疗开始后对该队列进行3至7年的监测。分析初始治疗结果和累积生存率,并确定治疗成功和生存的预测因素。
1407例MDR-TB患者中,75例(5.3%)在治疗开始时患有XDR-TB。失访率很高(453/1407;32%),XDR-TB患者的治疗成功率较低(29.3%对46.2%;P = 0.004),全因死亡率(49.3%对19.4%;P < 0.001)和结核病相关疾病死亡率(41.3%对11.8%;P < 0.001)均高于其他MDR-TB患者。多因素分析显示,XDR-TB的存在显著影响治疗成功率(优势比,0.23;95%置信区间[CI],0.08 - 0.64;P = 0.005)、全因死亡率(风险比,3.25;95% CI,1.91 - 5.53;P < 0.001)和结核病相关死亡率(风险比,4.45;95% CI,2.48 - 8.00;P < 0.001)。
韩国相当一部分MDR-TB患者患有XDR-TB,且XDR-TB是MDR-TB患者治疗结果和长期生存的最强预测因素。应实施适当的结核病控制政策以防止耐药性的进一步发展和传播。